MDA 2026: Trio of trials now testing Spinraza successor salanersen for SMA
Biogen has launched a trio of trials to test its new drug candidate for spinal muscular atrophy (SMA), salanersen, which aims to be a more convenient successor to the company’s approved SMA therapy…